Goubau P, Van Gerven V, Safary A, Delem A, Knops J, D'Hondt E, André F E, Desmyter J
Department of Microbiology, Rega Institute, Leuven, Belgium.
Vaccine. 1992;10 Suppl 1:S114-8. doi: 10.1016/0264-410x(92)90561-w.
A randomized double-blind comparison of five killed hepatitis A vaccine preparations was carried out with eligible medical student and staff volunteers. Vaccines were prepared in M RC-5 cells and formalin-inactivated. Three monthly injections of 1 ml in the deltoid muscle were given. Group A received the CLF strain at a dose of 360 ELISA units (El.U) in 0.5 mg aluminium hydroxide (n = 35). The other groups received the HM175 strain as follows: 180 El.U in 1 mg aluminium hydroxide (to group B, n = 42), 360 El.U in 0.5 mg aluminium hydroxide (to group C, n = 40), 360 El.U in 1 mg aluminium hydroxide (to group D, n = 39) and 720 El.U in 1 mg aluminium hydroxide (to group E, n = 43). The geometric mean anti-HAV concentration (GMC) measured in mIV/ml by an ELISA method one month after each injection were: group A, 223, 480, 1635; group B, 123, 221, 649; group C, 185, 365, 1085; group D, 144, 323, 1076; group E, 229, 646, 2521. At month 6, the GMC had fallen by approximately 20%. Seroconversion as measured by ELISA was 100% in groups A and E after one injection, and 100% in all groups after three injections; after two injections, only one subject in group C was still negative. The dose effect with HM175 vaccine was significant. There was a good correlation between ELISA and neutralization (radioimmunofocus inhibition test) titres. One month after the second dose, all subjects in groups A and E had both hepatitis A virus immunoglobulin M (HAV IgM) geometric mean titre, (GMT > 5000) and IgG (GMT > 25,000) as measured by a sensitive terminal dilution ELISA.(ABSTRACT TRUNCATED AT 250 WORDS)
对符合条件的医学生和工作人员志愿者进行了五种甲型肝炎灭活疫苗制剂的随机双盲比较。疫苗在MRC - 5细胞中制备并用福尔马林灭活。在三角肌中每月注射3次,每次1毫升。A组接受CLF毒株,剂量为360酶联免疫吸附测定单位(El.U),佐剂为0.5毫克氢氧化铝(n = 35)。其他组接受HM175毒株,具体如下:180 El.U加1毫克氢氧化铝(B组,n = 42),360 El.U加0.5毫克氢氧化铝(C组,n = 40),360 El.U加1毫克氢氧化铝(D组,n = 39),720 El.U加1毫克氢氧化铝(E组,n = 43)。每次注射后1个月通过酶联免疫吸附测定法以mIU/ml为单位测量的几何平均抗甲型肝炎病毒浓度(GMC)分别为:A组,223、480、1635;B组,123、221、649;C组,185、365、1085;D组,144、323、1076;E组,229、646、2521。在第6个月时,GMC下降了约20%。通过酶联免疫吸附测定法测得的血清转化率在A组和E组一次注射后为100%,所有组三次注射后均为100%;两次注射后,C组只有一名受试者仍为阴性。HM175疫苗的剂量效应显著。酶联免疫吸附测定法和中和(放射免疫聚焦抑制试验)滴度之间存在良好的相关性。第二次注射后1个月,A组和E组所有受试者通过灵敏的终点稀释酶联免疫吸附测定法测得的甲型肝炎病毒免疫球蛋白M(HAV IgM)几何平均滴度(GMT > 5000)和免疫球蛋白G(GMT > 25,000)均达标。(摘要截选至250词)